Navigation Links
Neurochem announces departure of two members of management team
Date:2/21/2008

LAVAL, QC, Feb. 21 /PRNewswire-FirstCall/ - In light of Neurochem Inc.'s (NASDAQ: NRMX; TSX: NRM) new strategic direction, the Company announces the departure, effective February 21, 2008, of two members of its senior management team, Dr. Andreas Orfanos, MBB. Ch, MBA, Executive Vice President, Strategic Planning and Scientific Affairs, and Ms. Christine Lennon, MBA, Vice President, Business Development. The possibility of their acting as consultants in respect of specific projects is being explored.

"On behalf of the Board of Directors and my colleagues, I want to express our gratitude to Dr. Orfanos and Ms. Lennon for their dedication and valuable contribution to Neurochem. We wish them every success in the future," said Dr. Francesco Bellini, Neurochem's Chairman, President and CEO.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the Neurochem group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of Neurochem Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of Neurochem Inc. for further risk factors that might affect the Neurochem group and its business.

Lise Hebert, PhD, Vice President, Corporate Communications, (450) 680-4572, lhebert@neurochem.com


'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
2. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
3. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
4. Neurochem to present at JPMorgan Healthcare Conference
5. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
6. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
7. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
8. Neurochem reports results for third quarter of fiscal 2007
9. Emergency Dentist 24/7(TM) Announces Worldwide Licensing Program
10. LCA-Vision Announces Quarterly Dividend Payment
11. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology: